Comparison of the effects of oral and intravenous proton pump inhibitors in preventing re-bleeding for patients with peptic ulcer
10.3760/cma.j.issn.1008-6706.2017.21.028
- VernacularTitle:口服与静脉注射质子泵抑制剂预防消化性溃疡再出血的效果比较
- Author:
Tao CHEN
1
;
Lili SHEN
;
Changming WU
;
Kai TANG
Author Information
1. 浙江省荣军医院嘉兴第三医院消化内科
- Keywords:
Proton pump inhibitor;
Peptic ulcer bleeding;
Oral;
Intravenous injection
- From:
Chinese Journal of Primary Medicine and Pharmacy
2017;24(21):3311-3313
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the clinical effects of oral proton pump inhibitor and intravenous proton pump inhibitor in preventing re-bleeding for patients with peptic ulcer.Methods From January 2014 to December 2015,149 patients with peptic ulcer bleeding who came to our hospital for treatment and were successfully stanched by endoscopic therapy were chosen as study subjects.They were randomly divided into oral group and intravenous group according to random number table.The clinical effects,including re-bleeding rate,mortality and volume of blood transfusion were compared between the two groups.Results The re-bleeding rates within 20 days of the oral group and intravenous group were 5.6％ and 5.1％,respectively,and there was no statistically significant difference between the two groups (x2 =0.02,P ＞ 0.05).The hospital stay of the oral group and intravenous group were (4.0 ± 0.4) d and (2.1 ± 0.6) d,respectively,and there was statistically significant difference between the two groups (t =22.90,P ＜0.05).The volume of blood transfusion of the oral group and intravenous group were (1 001 ±284.2)mL and (601.0 ± 197.9) mL,respectively,and there was no significant difference between the two groups (t =0.90,P ＞ 0.05).Both two groups had no death within 30d and during surgery.Conclusion For the patients who were successfully cured by endoscopic therapy,the clinical effect of oral proton pump inhibitor is similar to the effect of intravenous proton pump inhibitor,and oral proton pump inhibitor is more easy operating and lower economic burden than intravenous proton pump inhibitor.
